Sanuwave Health (NASDAQ:SNWV) Upgraded at Wall Street Zen

Key Points

• Sanuwave Health has been upgraded by Wall Street Zen from a "hold" rating to a "buy" rating, with a target price set at $55.00.
• The company's shares traded up 2.4%, reaching a price of $37.43, with a market capitalization of $320.78 million.
• In its latest earnings report, Sanuwave Health exceeded analyst expectations by reporting an EPS of $0.01, surpassing estimates of ($0.09).

Sanuwave Health (NASDAQ:SNWV - Get Free Report) was upgraded by analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a research report issued on Friday.

A number of other analysts also recently commented on the company. Northland Securities began coverage on Sanuwave Health in a research note on Wednesday, September 3rd. They issued an "outperform" rating and a $55.00 target price on the stock. Northland Capmk upgraded Sanuwave Health to a "strong-buy" rating in a research note on Wednesday, September 3rd. Roth Capital upped their target price on Sanuwave Health from $54.00 to $55.00 and gave the stock a "buy" rating in a research note on Friday, August 22nd. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Sanuwave Health in a research report on Saturday, September 27th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $55.00.

Sanuwave Health Stock Up 2.4%

Shares of SNWV traded up $0.86 during mid-day trading on Friday, reaching $37.43. The company had a trading volume of 25,144 shares, compared to its average volume of 52,488. Sanuwave Health has a 52-week low of $5.63 and a 52-week high of $46.58. The stock has a market capitalization of $320.78 million, a P/E ratio of -4.54 and a beta of 1.33. The stock has a 50 day moving average of $37.73 and a two-hundred day moving average of $33.87.

Sanuwave Health (NASDAQ:SNWV - Get Free Report) last issued its earnings results on Friday, August 8th. The company reported $0.01 EPS for the quarter, topping analysts' consensus estimates of ($0.09) by $0.10. The company had revenue of $10.16 million during the quarter, compared to analysts' expectations of $10.14 million. Sanuwave Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS.

Hedge Funds Weigh In On Sanuwave Health

Several hedge funds and other institutional investors have recently made changes to their positions in SNWV. Legal & General Group Plc purchased a new position in shares of Sanuwave Health in the second quarter valued at approximately $26,000. BNP Paribas Financial Markets purchased a new position in shares of Sanuwave Health in the second quarter valued at approximately $46,000. Strategic Investment Solutions Inc. IL purchased a new position in shares of Sanuwave Health in the first quarter valued at approximately $47,000. Police & Firemen s Retirement System of New Jersey purchased a new position in shares of Sanuwave Health in the second quarter valued at approximately $52,000. Finally, New York State Common Retirement Fund purchased a new position in shares of Sanuwave Health in the second quarter valued at approximately $102,000. Hedge funds and other institutional investors own 42.53% of the company's stock.

About Sanuwave Health

SANUWAVE Health, Inc, a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, and musculoskeletal and vascular structures.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.